Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313606 | 0.88 | MAOB (0.59) | NPC1RAB9ASMN1; SMN2MAOBKDM4E | |
| SCHEMBL5383914 | 0.87 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAOBKDM4E | |
| SCHEMBL6036170 | 0.86 | MAOB (0.59) | NPC1RAB9ASMN1; SMN2MAOBKDM4E | |
| SCHEMBL5097918 | 0.86 | MAOB (0.57) | SMN1; SMN2MAOBMEN1MAPTKMT2A | |
| SCHEMBL6036021 | 0.86 | L3MBTL1 (0.58) | RAB9ASMN1; SMN2MAOBKDM4EMEN1 | |
| SCHEMBL6035274 | 0.85 | CACNA1B (0.55) | MAOBKDM4ENR4A2NR4A1NR4A3 | |
| SCHEMBL6264178 | 0.85 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2MAOBKDM4E | |
| SCHEMBL17978729 | 0.84 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAOBKDM4E | |
| SCHEMBL3132024 | 0.84 | PARP10 (0.60) | NPC1RAB9ASMN1; SMN2MAOBKDM4E | |
| SCHEMBL9578124 | 0.84 | MAOB (0.56) | NPC1RAB9ASMN1; SMN2MAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-10835520-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| US-20190030010-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| US-10117861-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-06 | — | — | US | disclosed |
| EP-3150577-B1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20180042908-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9820980-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| US-20160213660-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-28 | — | — | US | disclosed |
| US-9340499-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-17 | — | — | US | disclosed |
| US-20150126486-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-07 | — | — | US | disclosed |
| US-8975409-B2 | Phenyl derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-20140235611-A1 | PHENYL DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| EP-2762466-A1 | PHENYL DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-08-06 | — | — | EP | disclosed |
| EP-1482935-B1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER LAMBERT CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1482935-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | Warner-Lambert Company LLC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074050-A1 | THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10117861-B2 | Phenyl derivative | S1PR2, S1PR1, S1PR3 | NPC1 644/4885RAB9A 3841/4885SMN1; SMN2 948/4885 |
| US-20150126486-A1 | PHENYL DERIVATIVE | S1PR2, S1PR1, S1PR3 | NPC1 518/4885RAB9A 3817/4885SMN1; SMN2 1281/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | NPC1 654/4885RAB9A 3067/4885SMN1; SMN2 782/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | NPC1 662/4885RAB9A 3063/4885SMN1; SMN2 787/4885 |
| US-20180042908-A1 | PHENYL DERIVATIVE | S1PR2, S1PR1, S1PR3 | NPC1 644/4885RAB9A 3841/4885SMN1; SMN2 948/4885 |
| US-20190030010-A1 | PHENYL DERIVATIVE | S1PR2, S1PR1, S1PR3 | NPC1 644/4885RAB9A 3841/4885SMN1; SMN2 948/4885 |
| US-20160213660-A1 | PHENYL DERIVATIVE | S1PR2, S1PR1, S1PR3 | NPC1 644/4885RAB9A 3841/4885SMN1; SMN2 948/4885 |
| US-20140235611-A1 | PHENYL DERIVATIVE | S1PR2, S1PR1, S1PR3 | NPC1 518/4885RAB9A 3817/4885SMN1; SMN2 1281/4885 |
| US-10835520-B2 | Phenyl derivative | S1PR2, S1PR1, S1PR3 | NPC1 644/4885RAB9A 3841/4885SMN1; SMN2 948/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | NPC1 654/4885RAB9A 3067/4885SMN1; SMN2 782/4885 |
| US-20030207924-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | NPC1 147/4885RAB9A 1874/4885SMN1; SMN2 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.